Viatris to Acquire Pacira BioSciences for $36.50/Share in $1.65B All-Cash Deal
PCRX sits 93% above its 52-week low of $18.8.
Summary
Pacira BioSciences agreed to be acquired by Viatris for $36.50 per share in cash, a $1.65 billion all-cash deal expected to close by end of 2026.
Key Events · M&A and Partnerships · PCRX
-
Definitive Merger Agreement Signed
Pacira entered into an Agreement and Plan of Merger with Viatris Inc. and Peach Purchaser Sub Inc. on October 8, 2026, for Viatris to acquire all outstanding Pacira shares at $36.50 per share in cash, representing approximately $1.65 billion in equity value.
-
Tender Offer and Second-Step Merger
Viatris will commence a cash tender offer within 15 business days, with initial expiration 10 business days after commencement. Following completion, a second-step merger under Section 251(h) of the DGCL will occur with no shareholder vote required.
-
Board Approval and Recommendation
The Pacira Board unanimously determined the transaction is fair and in the best interest of stockholders, approved the merger agreement, and recommends stockholders tender their shares. Goldman Sachs & Co. LLC provided a fairness opinion.
-
Termination Fee and Deal Protections
Pacira agreed to pay a $62 million termination fee if the deal is terminated under specified circumstances, including to accept a superior offer. The agreement includes customary no-shop provisions and a fiduciary out.
Analysis · PCRX · Life Sciences
Pacira BioSciences has entered into a definitive merger agreement with Viatris Inc. under which Viatris will acquire all outstanding Pacira shares for $36.50 per share in cash, representing an aggregate equity value of approximately $1.65 billion. The transaction will be effected through a cash tender offer followed by a second-step merger under Section 251(h) of the DGCL, with no shareholder vote required. The Pacira Board unanimously approved the deal and recommends stockholders tender their shares. The merger agreement includes a $62 million termination fee payable by Pacira under specified circumstances, including if Pacira terminates to accept a superior offer. The tender offer is expected to commence within 15 business days, with an initial expiration 10 business days after commencement, and the deal is expected to close by the end of 2026, subject to customary conditions including HSR clearance and the tender of a majority of outstanding shares. This is a thesis-altering event for Pacira shareholders, locking in a premium to the pre-announcement trading range and effectively capping the stock near the offer price pending completion.
How filings like this one have moved
In the 30 days to Oct 8, 2026, 42.9% of the 331 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.63%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PCRX was trading at $36.34 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1B. The 52-week trading range was $18.80 to $27.66. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.